Federal reporting says the FDA blocked publication of several studies that found rare serious side effects from COVID and shingles vaccines, prompting fresh questions about transparency.

Former NASA administrator Jim Bridenstine will run Rockville-based Quantum Space as CEO, joining a startup building refuelable, maneuverable Ranger spacecraft aimed at defense missions. The company says Ranger Prime is now targeting a 2027 launch window.

A West Health–Gallup poll finds many Americans consult AI for health questions — and roughly 14 million say AI advice led them to skip care. Stanford’s chief data scientist weighs in.

DOJ's rescheduling of medical cannabis is opening investor pipelines for cannabis drug startups, prompting private raises and IPO talk while banks and state rules still complicate the picture.

Charles Lieber, convicted in 2021, now heads i‑BRAIN in Shenzhen with a new ASML nanofab and primate infrastructure — a move that raises policy and security questions.

The Supreme Court heard a key skinny‑label case that could redefine when generic marketing becomes patent 'inducement' — and could affect drug prices nationwide.

Arlington Capital has bought Enercon and will fold it into Pond & Company to form a roughly 2,700‑person engineering firm based in the Atlanta area.

The Commerce Department told U.S. chip‑tool makers to pause some shipments to Hua Hong, a move that could slow the company’s push toward 7nm chips and hit vendor sales.

China’s NDRC ordered the cancellation of Meta’s acquisition of Manus, forcing parties to withdraw and raising new risks for cross‑border AI deals. The move unsettles Bay Area dealmaking.

Large phase‑3 trials show AD109, a once‑nightly pill, cut sleep‑apnea severity by about half; dry mouth and insomnia were common and regulators will review safety.

President Trump abruptly removed members of the National Science Board, stripping an advisory panel that helps govern the NSF and prompting immediate backlash from universities and lawmakers.

3D imaging and AI of fossil beaks suggest finned octopuses up to about 62 feet long once patrolled Cretaceous seas. The jaws show heavy wear consistent with crushing hard prey.

Interim REMAIN‑1 results suggest a one‑time endoscopic "gut reset" can help maintain weight after stopping GLP‑1 drugs. Topline pivotal data are expected in Q4 2026.